Pamiparib

帕米帕利

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NamePamiparib
Drug Alias Name百汇泽PARTRUVIXBGB-290BeiGene-290PARPi - BeiGene
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitorsPoly (ADP-Ribose) Polymerase 2 inhibitors
TargetsPoly (ADP-Ribose) Polymerase 2Poly (ADP-Ribose) polymerase 1
Therapy Area/IndicationsLow-grade GliomaSolid tumoursProstatic Neoplasms, Castration-Resistant +[15] 
Global Approved IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms
Approved Indications in ChinaFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2021/04/30
Country/TerritoryCzechiaBelgiumUnited States +[26] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeOne Medicines Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesUniversity Of California San FranciscoBeigene (Usa) IncBeOne Medicines Ltd +[8] 
Inactive CompaniesBeOne Medicines (Beijing) Co Ltd
Active IndicationsLow-grade GliomaSolid tumoursProstatic Neoplasms, Castration-Resistant +[13] 
Inactive IndicationsBreast NeoplasmsCarcinosarcoma

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBankKEGG